SANICKA receives Biolocity Launch Award

SANICKA receives Biolocity Launch Award

The Biolocity program has selected five promising and patient-focused technologies for its new cohort of Biolocity Launch, a year-long collaboration that helps faculty members commercialize their innovations. We are pleased to announced that our  project was selected!

 

Sanicka: A clinical decision support tool to aid treatment selection and optimization for leukemia patients. Principal Investigators: Ana Quiroga, Ph.D., and Sakis Mantalaris, Ph.D., (Georgia Tech); Nicki Panoskaltsis, M.D., Ph.D. (Emory University).

Learn more at here

 

We are so grateful for Biolocity’s support. Since 2015, the program has awarded more than $8.7 million across 58 projects, generating over 10 times that much follow-on investment.

Learn more about Biolocity at biolocity.org.

Jarquin Wins 2 Years of Support from Hematology Society

Jarquin Wins 2 Years of Support from Hematology Society

Congratulations are in order

to our third year of doctoral studies student, PJ Jarquin! Jarquin has won a 2021 Minority Hematology Graduate Award, which includes two years of funding from the professional society for stipends and research costs along with connections to mentors and other researchers studying blood and blood disorders. PJ studies red blood cell development in health and disease here in the BSEL. He previously received a National Science Foundation Graduate Research Fellowship and an Emory Centennial Scholars Fellowship.

The Minority Hematology Graduate Award encourages graduate students from historically underrepresented minority groups to pursue careers in academic hematology, according to the society. The award comes with society membership, invitations to present research, and opportunities to meet leaders in the field.

 

PJ has his eyes on a career as a scientist at a federal research agency. You can read more from PJ and about his accomplishment here

ACS Research Podcast: Female Founders Program at Georgia Tech

ACS Research Podcast: Female Founders Program at Georgia Tech

On this weeks American Cancer Society TheoryLab podcast, our post-doc, Ana Quiroga Campano, joined 3 other amazing women to talk about the Female Founders program at Georgia Tech:

-Female-led startups
-Scientist-entrepreneurs
-New technologies

 

Find the full podcast below:

 

New Member – Alejandro Gutierrez

New Member – Alejandro Gutierrez

The BSEL would like to welcome Alejandro De Janon Gutierrez to the lab!

 

Alejandro received his degree of chemical engineer at the National Technological University  (UTN), Buenos Aires, Argentina. During his final year of study and after obtaining his degree, he worked in process risk management consulting for oil, chemical, food and pharmaceutical companies. After being awarded with a Fulbright Scholarship, Alejandro continued his studies and obtained his Master in Biotechnology at Texas A&M. During his masters he worked on bioprocessing and downstream purification of proteins. His research on this field led him to an internship at Merck & Co. where he gained experience on monoclonal antibodies manufacturing.

 

After completing his masters, Alejandro came to Georgia Tech to pursue his PhD in Bioengineering. His research is focused on developing a 3D in vitro leukemia model, analyzing cancer metabolism to culture leukemic cells.

 

 

Publication Announcement – Cancer Immunology, Immunotherapy

Publication Announcement – Cancer Immunology, Immunotherapy

We are pleased to announce that our Dr. Panoskaltsis’ work on TGN1412-induced cytokine storm has been published in Cancer Immunology, Immunotherapy. The article entitled “Myelopoiesis of acute inflammation: lessons from TGN1412-induced cytokine storm” highlights TGN1412, a superagonist monoclonal antibody targeting CD28, which caused cytokine storm in six healthy volunteers in a first-in-man study in 2006. The TGN1412-induced cytokine storm offers unique insights into the pathogenesis of anemia of inflammation and offer immunological correlates and insights into the hematopoiesis of inflammation, aging, and BM failure disorders such as MDS..

http://link.springer.com/article/10.1007/s00262-020-02702-9 

Our Paper was selected by ACS as the Editors’ Choice

Our Paper was selected by ACS as the Editors’ Choice

The BSEL’s most recent paper has received the great honor of being chosen as the American Chemical Society’s Editors’ Choice! The article entitled “Linking Engineered Gene Circuit Kinetic Modeling to Cellulose Biosynthesis Prediction in Escherichia coli: Toward Bioprocessing of Microbial Cell Factories” was featured in Industrial & Engineering Chemistry Research in which we present a rational modeling approach linking the designed engineered gene circuit to bioprocess kinetics, whereby the engineered gene circuit model informs the formulation of product biosynthesis and is coupled to microbial growth. This kinetic model is a practical and complementary approach to systems and synthetic biology for the robust operation of microbial cell factory systems and their bioprocess applications. Read more here

NSF I-Corps Team 1656 BioProcess Optimizer

NSF I-Corps Team 1656 BioProcess Optimizer

Over the course of 7 weeks this summer, BSEL members Dr. Ana Quiroga and Esther Chen along with their business mentor, Nakia Melecio, from Georgia Tech’s ATDC traveled all around the US and Switzerland to visit biotech hubs as a part of the national NSF I-Corps (D.C. node). The aim of this intense program is to get academic researchers out of their comfort zone and into the field to evaluate the commercial potential of their technology. Our efforts paid off and we completed 212 (!) interviews and identified the following customer segments: manufacturing of biomolecules for human therapeutics, viruses for gene therapies, mesenchymal stem cells (MSCs) for tissue regeneration and immunomodulation, T cells for CAR-T therapies, animal vaccines, and clean meat production. Our team interviewed a wide variety of professionals, from machine learning experts, to upstream process engineers, to members of the CDC, and clinicians. From these numerous discussions, we learned about the pains each industry faces and how our technology could potentially fill the gap. Moving forward, we will continue to learn about our customer segment and continue to work towards bringing our technology to the market.

We would like to thank all of those who supported us throughout the journey, including friends, family, BSEL members, and especially Drs. Mantalaris and Panoskaltsis for allowing us to seize this opportunity and make the most of this incredible experience.

Publication Announcement – CORDIS

Publication Announcement – CORDIS

We are pleased to announce that our lab’s BioBlood project has been selected for publication in the “Results in Brief” section of the European Commission’s CORDIS (Community Research and Development Information Service). The article entitled “Development of a Bio-Inspired Blood Factory for Personalized Healthcare” highlights our BioBlood platform which represents an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal haematopoiesis. Our platform offers a dynamic, 3D perfusion bone marrow biomimicry in a bioreactor. It produces multiple cell types simultaneously and has the potential to be used for transfusion purposes or to discover personalized drug targets.

https://cordis.europa.eu/project/rcn/110516/brief/en?WT.mc_id=exp